18:41 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG-positive cervical and breast cancers. In cervical cancer patient samples,...
18:56 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing...
18:55 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Updated Phase I data

Updated data from 13 patients with adenoid cystic carcinoma (ACC) in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that once-daily 10-300 mg oral amcasertib led to a median PFS...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Additional Phase I data

Data from 15 patients with squamous cell carcinoma of the head and neck (SCCHN) and 5 patients with parotid/salivary tumors in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that...
07:00 , May 12, 2016 |  BC Innovations  |  Tools & Techniques

Modeling with interference

While much of the focus on CRISPR-based gene editing has been on its potential to change the way genetic disorders are treated, the biggest and most immediate impact of the rapidly emerging technology so far...
07:00 , Apr 25, 2013 |  BC Innovations  |  Cover Story

Super-enhancing discovery

Boston researchers have detailed a class of regulatory elements, dubbed super-enhancers, that control the expression of genes, including oncogenes, that are key to determining cellular identity.1,2 The findings may explain how some compounds that broadly...
07:00 , Aug 30, 2012 |  BC Innovations  |  Tools & Techniques

Eliminating teratomas

A University of California, San Diego team has developed a genetic method to prevent embryonic stem cell therapies from forming cancerous teratomas following transplantation.1 The method was safe in mice, although questions remain about whether...
07:00 , Jul 1, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Nanog homeobox (NANOG) In vitro and mouse studies suggest that inhibiting NANOG could help treat...